TIGIT and immune system disorder: The above results suggest that co-expression of TIM-3/TIGIT and TIM-3/2B4 cells in patients with NPC is associated with aging-mediated immune dysfunction and that TIM-3/TIGIT and TIM-3/2B4 promote tumor progression in patients with NPC aged ≥ 52 years.